ArticleEuropean heart journal. Cardiovascular Imaging2024
Additional value of cardiac magnetic resonance parametric mapping in tissue characterization of common benign paediatric cardiac tumours.
Article in European heart journal. Cardiovascular Imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiac Hemangioma in the Right Atrium: Diagnostic Challenges, Imaging Clues, and a Novel Algorithm for Differential Diagnosis.Life (Basel, Switzerland) · 2025Article
- Cardiac Hemangiomas: A Five-Year Systematic Review of Diagnosis, Treatment, and Outcomes.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsCardiac magnetic resonance (CMR) parametric mapping is underexplored in cardiac tumours. To evaluate the contribution of mapping sequences on the characterization of paediatric tumours. METHODS AND
resultsAll paediatric patients referred for cardiac tumours at Bambino Gesù Children's Hospital from June 2017 to November 2023, who underwent CMR with mapping sequences, were included. The diagnosis of tumour type was performed according to signal characteristics on different sequences. Mass parametric mapping for each subtype and interobserver variability was assessed. Sixteen patients were enrolled. The mean age at CMR was 7 ± 5 years. 'Traditional' mass type assessment diagnosed haemangioma (Group A) in three patients (19%), fibroma (Group B) in four patients (25%), rhabdomyoma (Group C) in six patients (37%), and lipoma (Group D) in three patients (19%). The analysis of variance analysis revealed significant differences in mass native T1 and mass extracellular volume (ECV) values among the four subgroups (P < 0.001 for both comparisons). The mean native T1 and ECV values were respectively 1465 ± 158 ms and 54 ± 4% for Group A, 860 ± 118 ms and 93 ± 4% for Group B, 1007 ± 57 ms and 23 ± 5% for Group C, and 215 ± 13 ms and 0 ± 0% for Group D.
conclusionMass mapping analysis is feasible and reproducible in children. ECV values provide the most accurate differentiation. Mass ECV consistently resembles normal myocardium in rhabdomyoma, is extremely high (approaching 100%) in fibroma, equals to zero in lipoma, and matches blood pool ECV (1-Hct) in haemangioma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.